{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:15Z","timestamp":1788265095278,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EFS2","EFSA Journal"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on S\u2010acetyl glutathione (SAG) as a novel food (NF) pursuant to Regulation (EU) 2015\/2283. The NF consists of &gt;\u200997% (w\/w) SAG, which is an acetylated tripeptide (i.e. cysteine, glutamic acid and glycine) obtained through chemical synthesis. The information provided on the production process, composition and specifications of the NF did not raise safety concerns. The NF contains perchlorate, although its intake through this NF, added to the background dietary exposure, remains below the tolerable daily intake (TDI) established by EFSA, across the age groups. The NF is proposed to be used as a food supplement and as food for special medical purposes at a maximum dose of 300 mg NF\/day, targeting the general population excluding individuals below 10\u2009years of age, and pregnant or lactating women. A BMDL10 of 877 mg\/kg bw per day was derived for the increase in the liver\u2010to\u2010body weight ratio from benchmark dose modelling, leading to a safe dose of 4.39 mg\/kg bw per day after applying an uncertainty factor of 200. This corresponds to safe intake levels of 190, 269 and 307 mg\/day for young adolescents (from 10 to &lt;\u200914\u2009years), older adolescents (from 14 to &lt;\u200918\u2009years) and adults, respectively. Human clinical data on orally administered glutathione support the safety of the NF in adults. The Panel concludes that the NF is safe at the proposed conditions of use of 300 mg\/day for adults, excluding pregnant and lactating women. For young and older adolescents, the Panel considers that the NF is safe when consumed at intake levels up to 190 and 269 mg\/day, respectively, assuming similar tolerance on a body weight basis as compared to adults.<\/jats:p>","DOI":"10.2903\/j.efsa.2026.10258","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:45:16Z","timestamp":1788263116000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of S\u2010acetyl glutathione as an novel food pursuant to Regulation (EU) 2015\/2283"],"prefix":"10.2903","volume":"24","author":[{"name":"EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Turck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monta\u00f1a","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Castenmiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"De Henauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Jos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Maciuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Mangelsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breige","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Androniki","family":"Naska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Pentieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Siani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Thies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cubadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Gundert\u2010Remy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Marcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Moldeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Neuh\u00e4user\u2010Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Multari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Magani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Ildico","family":"Hirsch\u2010Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"issue":"9","key":"10.2903\/j.efsa.2026.10258_ref1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/acm.2010.0716","article-title":"Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers","volume":"17","author":"Allen","year":"2011","journal-title":"Journal of Alternative and Complementary Medicine"},{"issue":"2","key":"10.2903\/j.efsa.2026.10258_ref2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/09546631003801619","article-title":"Glutathione as an oral whitening agent: A randomized, double\u2010blind, placebo\u2010controlled study","volume":"23","author":"Arjinpathana","year":"2012","journal-title":"The Journal of Dermatological Treatment"},{"issue":"6","key":"10.2903\/j.efsa.2026.10258_ref3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/MPG.0000000000002948","article-title":"Oral glutathione and growth in cystic fibrosis: A multicenter, randomized, placebo\u2010controlled, double\u2010blind trial","volume":"71","author":"Bozic","year":"2020","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.2903\/j.efsa.2026.10258_ref4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nut.2016.12.018","article-title":"Medium\u2010term effect of sublingual l\u2010glutathione supplementation on flow\u2010mediated dilation in subjects with cardiovascular risk factors","volume":"38","author":"Campolo","year":"2017","journal-title":"Nutrition"},{"issue":"5","key":"10.2903\/j.efsa.2026.10258_ref5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/gut.6.5.472","article-title":"Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis","volume":"6","author":"Cook","year":"1965","journal-title":"Gut"},{"issue":"2","key":"10.2903\/j.efsa.2026.10258_ref6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jocd.14137","article-title":"The effects of the oral supplementation of L\u2010cystine associated with reduced L\u2010glutathione\u2010GSH on human skin pigmentation: A randomized, double\u2010blinded, benchmark\u2010 and placebo\u2010controlled clinical trial","volume":"21","author":"Duperray","year":"2022","journal-title":"Journal of Cosmetic Dermatology"},{"key":"10.2903\/j.efsa.2026.10258_ref7","doi-asserted-by":"crossref","unstructured":"EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) . (2025). Update of the Scientific Opinion on the risks for human health related to the presence of perchlorate in food. EFSA Journal, 23(5), 9393. https:\/\/doi.org\/10.2903\/j.efsa.2025.9393","DOI":"10.2903\/j.efsa.2025.9393"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10258_ref8.1","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) . (2021). Guidance on the preparation and submission of an application for authorisation of a novel food in the context of regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10258_ref8.2","doi-asserted-by":"crossref","unstructured":"(EU) 2015\/22831 (revision 1)2. EFSA Journal, 19(3), 6555. https:\/\/doi.org\/10.2903\/j.efsa.2021.6555","DOI":"10.2903\/j.efsa.2021.6555"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10258_ref9.1","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) Turck, D., Bohn, T., Castenmiller, J., de Henauw, S., Hirsch\u2010Ernst, K. I., Maciuk, A., Mangelsdorf, I., McArdle, H. J., Naska, A., Pentieva, K., Siani, A., Thies, F., Tsabouri, S., Vinceti, M., Aguilera G\u00f3mez, M., Cubadda, F., Frenzel, T., Heinonen, M., \u2026 Knutsen, H. K. (2024) Guidance on the scientific requirements for an application for authorisation of a novel food in the context of Regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10258_ref9.2","doi-asserted-by":"crossref","unstructured":"(EU) 2015\/2283. EFSA Journal, 22(9), 8961. https:\/\/doi.org\/10.2903\/j.efsa.2024.8961","DOI":"10.2903\/j.efsa.2024.8961"},{"key":"10.2903\/j.efsa.2026.10258_ref10","doi-asserted-by":"crossref","unstructured":"EFSA Scientific Committee . (2021). Guidance on technical requirements for regulated food and feed product applications to establish the presence of small particles including nanoparticles. EFSA Journal, 19(8), 6769. https:\/\/doi.org\/10.2903\/j.efsa.2021.6769","DOI":"10.2903\/j.efsa.2021.6769"},{"key":"10.2903\/j.efsa.2026.10258_ref11","doi-asserted-by":"crossref","unstructured":"Fanelli, S., Francioso, A., Cavallaro, R., d'Erme, M., Putignano, P., Miraglia, N., & Mosca, L. (2018). Oral administration of S\u2010acetyl\u2010glutathione: Impact on the levels of glutathione in plasma and in erythrocytes of healthy volunteers. International Journal of Clinical Nutrition & Dietetics, 4, 134. https:\/\/doi.org\/10.15344\/2456\u20108171\/2018\/134","DOI":"10.15344\/2456-8171\/2018\/134"},{"issue":"2","key":"10.2903\/j.efsa.2026.10258_ref12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijd.12999","article-title":"An open\u2010label, single\u2010arm trial of the safety and efficacy of a novel preparation of glutathione as a skin\u2010lightening agent in Filipino women","volume":"55","author":"Handog","year":"2016","journal-title":"International Journal of Dermatology"},{"issue":"1","key":"10.2903\/j.efsa.2026.10258_ref13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","article-title":"Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: An open\u2010label, single\u2010arm, multicenter, pilot study","volume":"17","author":"Honda","year":"2017","journal-title":"BMC Gastroenterology"},{"issue":"1","key":"10.2903\/j.efsa.2026.10258_ref15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12970-018-0235-x","article-title":"Eight weeks of resistance training in conjunction with glutathione and L\u2010citrulline supplementation increases lean mass and has no adverse effects on blood clinical safety markers in resistance\u2010trained males","volume":"15","author":"Hwang","year":"2018","journal-title":"Journal of the International Society of Sports Nutrition"},{"key":"10.2903\/j.efsa.2026.10258_ref16","doi-asserted-by":"crossref","first-page":"CR677","DOI":"10.12659\/MSM.882125","article-title":"A clinical trial of glutathione supplementation in autism spectrum disorders","volume":"17","author":"Kern","year":"2011","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"10.2903\/j.efsa.2026.10258_ref17","doi-asserted-by":"crossref","unstructured":"Lai, C. Y., Cheng, S. B., Lee, T. Y., Hsiao, Y. F., Liu, H. T., & Huang, Y. C. (2020). Impact of glutathione and vitamin B\u20106 in cirrhosis patients: A randomized controlled trial and follow\u2010up study. Nutrients, 12(7), 1978. https:\/\/doi.org\/10.3390\/nu12071978","DOI":"10.3390\/nu12071978"},{"issue":"11","key":"10.2903\/j.efsa.2026.10258_ref18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1089\/jir.2014.0210","article-title":"Liposomal glutathione supplementation restores TH1 cytokine response to mycobacterium tuberculosis infection in HIV\u2010infected individuals","volume":"35","author":"Ly","year":"2015","journal-title":"Journal of Interferon & Cytokine Research"},{"issue":"10","key":"10.2903\/j.efsa.2026.10258_ref19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nri3294","article-title":"Unconventional recognition of peptides by T cells and the implications for autoimmunity","volume":"12","author":"Mohan","year":"2012","journal-title":"Nature Reviews. Immunology"},{"key":"10.2903\/j.efsa.2026.10258_ref20","unstructured":"OECD (Organisation for Economic Co\u2010 Operation and Development) . (1998). OECD principles of good laboratory practice (as revised in 1997). OECD serieson principles of good laboratory practice and compliance monitoring, number 1, ENV\/MC\/CHEM(98)17, 41 pp."},{"issue":"2","key":"10.2903\/j.efsa.2026.10258_ref21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00394-014-0706-z","article-title":"Randomized controlled trial of oral glutathione supplementation on body stores of glutathione","volume":"54","author":"Richie","year":"2015","journal-title":"European Journal of Nutrition"},{"key":"10.2903\/j.efsa.2026.10258_ref22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.redox.2015.07.012","article-title":"Effects of N\u2010acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study","volume":"6","author":"Schmitt","year":"2015","journal-title":"Redox Biology"},{"issue":"9","key":"10.2903\/j.efsa.2026.10258_ref23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1139\/apnm-2020-1099","article-title":"The effects of 3\u2009weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: A randomized trial","volume":"46","author":"S\u00f8nderg\u00e5rd","year":"2021","journal-title":"Applied Physiology, Nutrition, and Metabolism"},{"key":"10.2903\/j.efsa.2026.10258_ref24","unstructured":"Unpublished . (2023a). (claimed as proprietary by the applicant). S\u2010acetyl\u2010L\u2010glutathione and L\u2010glutathione comparative pharmacokinetic study in healthy volunteers."},{"key":"10.2903\/j.efsa.2026.10258_ref25","unstructured":"Unpublished . (2023b). (claimed as proprietary by the applicant). Bacterial reverse mutation test (GLP, OECD TG 471). Study no. FSR\u2010IPL 220511."},{"key":"10.2903\/j.efsa.2026.10258_ref26","unstructured":"Unpublished . (2023c). (claimed as proprietary by the applicant). In vitro mammalian cells micronucleus test (GLP, OECD TG 487). Study no. FSR\u2010IPL 220512."},{"key":"10.2903\/j.efsa.2026.10258_ref27","unstructured":"Unpublished . (2023d). (claimed as proprietary by the applicant). 2\u2010Week Once Daily Oral Gavage Toxicity Study with S\u2010Acetyl Glutathione in Rats (GLP, OECD TG 487). Study no. 8501006."},{"key":"10.2903\/j.efsa.2026.10258_ref28","unstructured":"Unpublished . (2023e). (claimed as proprietary by the applicant). 13\u2010Week Once Daily Oral Gavage Toxicity Study with S\u2010Acetyl Glutathione in Rats with a 4\u2010Week Recovery (GLP, OECD TG 487). Study no. 8501002."},{"issue":"6","key":"10.2903\/j.efsa.2026.10258_ref29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/MPG.0000000000000738","article-title":"Oral reduced L\u2010glutathione improves growth in pediatric cystic fibrosis patients","volume":"60","author":"Visca","year":"2015","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"8","key":"10.2903\/j.efsa.2026.10258_ref30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/ijd.15573","article-title":"Combination of topical and oral glutathione as a skin\u2010whitening agent: A double\u2010blind randomized controlled clinical trial","volume":"60","author":"Wahab","year":"2021","journal-title":"International Journal of Dermatology"},{"key":"10.2903\/j.efsa.2026.10258_ref31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CCID.S128339","article-title":"Glutathione and its antiaging and antimelanogenic effects","volume":"10","author":"Weschawalit","year":"2017","journal-title":"Clinical, Cosmetic and Investigational Dermatology"}],"container-title":["EFSA Journal"],"original-title":[],"link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.2903\/j.efsa.2026.10258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.2903\/j.efsa.2026.10258\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:45:19Z","timestamp":1788263119000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.2903\/j.efsa.2026.10258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.2903\/j.efsa.2026.10258","relation":{},"ISSN":["1831-4732","1831-4732"],"issn-type":[{"value":"1831-4732","type":"print"},{"value":"1831-4732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}